A promising inactivated whole-virion SARS-CoV-2 vaccine

doi:10.1016/S1473-3099(20)30832-X

. 2021 Jan;21(1):2-3.

doi: 10.1016/S1473-3099(20)30832-X. Epub 2020 Oct 15.

A promising inactivated whole-virion SARS-CoV-2 vaccine

Irina Isakova-Sivak¹, Larisa Rudenko²

Affiliations

¹ Institute of Experimental Medicine, Saint Petersburg 197376, Russia.
² Institute of Experimental Medicine, Saint Petersburg 197376, Russia. Electronic address: vaccine@mail.ru.

PMID: 33069282
PMCID: PMC7561316
DOI: 10.1016/S1473-3099(20)30832-X

A promising inactivated whole-virion SARS-CoV-2 vaccine

Irina Isakova-Sivak et al. Lancet Infect Dis. 2021 Jan.

. 2021 Jan;21(1):2-3.

doi: 10.1016/S1473-3099(20)30832-X. Epub 2020 Oct 15.

Authors

Irina Isakova-Sivak¹, Larisa Rudenko²

Affiliations

¹ Institute of Experimental Medicine, Saint Petersburg 197376, Russia.
² Institute of Experimental Medicine, Saint Petersburg 197376, Russia. Electronic address: vaccine@mail.ru.

PMID: 33069282
PMCID: PMC7561316
DOI: 10.1016/S1473-3099(20)30832-X

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Cited by

Effectiveness and Safety of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) among Healthcare Workers: A Seven-Month Follow-Up Study at Fifteen Central Hospitals.
Ashmawy R, Kamal E, Amin W, Sharaf S, Kabeel S, Albiheyri R, El-Maradny YA, Hassanin E, Elsaka N, Fahmy O, Awd A, Aboeldahab H, Nayle M, Afifi M, Ibrahim M, Rafaat R, Aly S, Redwan EM. Ashmawy R, et al. Vaccines (Basel). 2023 Apr 24;11(5):892. doi: 10.3390/vaccines11050892. Vaccines (Basel). 2023. PMID: 37242996 Free PMC article.
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.
Mohraz M, Salehi M, Tabarsi P, Abbasi-Kangevari M, Ghamari SH, Ghasemi E, Amini Pouya M, Rezaei N, Ahmadi N, Heidari K, Malekpour MR, Nasiri M, Amirzargar AA, Saeedi Moghaddam S, Larijani B, Hosseini H. Mohraz M, et al. BMJ Open. 2022 Apr 8;12(4):e056872. doi: 10.1136/bmjopen-2021-056872. BMJ Open. 2022. PMID: 35396297 Free PMC article. Clinical Trial.
A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity.
Bellier B, Saura A, Luján LA, Molina CR, Luján HD, Klatzmann D. Bellier B, et al. Front Immunol. 2022 Feb 25;13:837443. doi: 10.3389/fimmu.2022.837443. eCollection 2022. Front Immunol. 2022. PMID: 35281065 Free PMC article.
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, Ansari M, Anwar S. Malik JA, et al. J Infect Public Health. 2022 Feb;15(2):228-240. doi: 10.1016/j.jiph.2021.12.014. Epub 2022 Jan 5. J Infect Public Health. 2022. PMID: 35042059 Free PMC article. Review.
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects.
Zhang J, Xing S, Liang D, Hu W, Ke C, He J, Yuan R, Huang Y, Li Y, Liu D, Zhang X, Li L, Lin J, Li W, Teng X, Liu Y, Wen W, Kang Q, Wang D, Liu W, Xu J. Zhang J, et al. Front Cell Infect Microbiol. 2021 Dec 16;11:791660. doi: 10.3389/fcimb.2021.791660. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34976867 Free PMC article.

See all "Cited by" articles

References

1. Tregoning JS, Brown ES, Cheeseman HM. Vaccines for COVID-19. Clin Exp Immunol. 2020 doi: 10.1111/cei.13517. published online Sept 15. - DOI - PMC - PubMed
1. Jackson LA, Anderson EJ, Rouphael NG. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2022483. published online July 14. - DOI - PMC - PubMed
1. Zhu FC, Guan XH, Li YH. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. - PMC - PubMed
1. Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed
1. Logunov DY, Dolzhikova IV, Zubkova OV. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Tregoning JS, Brown ES, Cheeseman HM. Vaccines for COVID-19. Clin Exp Immunol. 2020 doi: 10.1111/cei.13517. published online Sept 15. - DOI - PMC - PubMed

[2] Tregoning JS, Brown ES, Cheeseman HM. Vaccines for COVID-19. Clin Exp Immunol. 2020 doi: 10.1111/cei.13517. published online Sept 15. - DOI - PMC - PubMed

[3] Jackson LA, Anderson EJ, Rouphael NG. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2022483. published online July 14. - DOI - PMC - PubMed

[4] Jackson LA, Anderson EJ, Rouphael NG. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2022483. published online July 14. - DOI - PMC - PubMed

[5] Zhu FC, Guan XH, Li YH. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. - PMC - PubMed

[6] Zhu FC, Guan XH, Li YH. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. - PMC - PubMed

[7] Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed

[8] Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed

[9] Logunov DY, Dolzhikova IV, Zubkova OV. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. - PMC - PubMed

[10] Logunov DY, Dolzhikova IV, Zubkova OV. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A promising inactivated whole-virion SARS-CoV-2 vaccine

Affiliations

A promising inactivated whole-virion SARS-CoV-2 vaccine

Authors

Affiliations

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous